Odonate Therapeutics Inc (NASDAQ:ODT) CEO Kevin C. Tang bought 20,000 shares of Odonate Therapeutics stock in a transaction dated Wednesday, December 12th. The shares were purchased at an average cost of $15.60 per share, for a total transaction of $312,000.00. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.
ODT traded down $0.62 during trading on Thursday, hitting $15.14. The company had a trading volume of 14,672 shares, compared to its average volume of 51,904. The stock has a market capitalization of $408.59 million and a PE ratio of -6.55. Odonate Therapeutics Inc has a 1-year low of $14.06 and a 1-year high of $32.00.
Odonate Therapeutics (NASDAQ:ODT) last posted its quarterly earnings results on Tuesday, October 23rd. The company reported ($0.98) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.96) by ($0.02). On average, sell-side analysts predict that Odonate Therapeutics Inc will post -3.49 earnings per share for the current year.
A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Vanguard Group Inc raised its holdings in Odonate Therapeutics by 18.5% in the third quarter. Vanguard Group Inc now owns 316,733 shares of the company’s stock valued at $6,148,000 after acquiring an additional 49,528 shares in the last quarter. Federated Investors Inc. PA acquired a new stake in Odonate Therapeutics in the third quarter valued at $68,000. Vanguard Group Inc. raised its holdings in Odonate Therapeutics by 18.5% in the third quarter. Vanguard Group Inc. now owns 316,733 shares of the company’s stock valued at $6,148,000 after acquiring an additional 49,528 shares in the last quarter. Tang Capital Management LLC raised its holdings in Odonate Therapeutics by 11.2% in the third quarter. Tang Capital Management LLC now owns 13,796,747 shares of the company’s stock valued at $267,795,000 after acquiring an additional 1,384,409 shares in the last quarter. Finally, Tower Research Capital LLC TRC raised its holdings in Odonate Therapeutics by 222.8% in the third quarter. Tower Research Capital LLC TRC now owns 5,288 shares of the company’s stock valued at $102,000 after acquiring an additional 3,650 shares in the last quarter. 92.23% of the stock is currently owned by hedge funds and other institutional investors.
COPYRIGHT VIOLATION NOTICE: “Odonate Therapeutics Inc (ODT) CEO Kevin C. Tang Acquires 20,000 Shares” was first published by WKRB News and is the property of of WKRB News. If you are accessing this story on another site, it was stolen and reposted in violation of US & international trademark and copyright law. The original version of this story can be read at https://www.wkrb13.com/2018/12/14/odonate-therapeutics-inc-odt-ceo-kevin-c-tang-acquires-20000-shares.html.
Odonate Therapeutics Company Profile
Odonate Therapeutics, Inc, a pharmaceutical company, develops therapeutics for the treatment of cancer. It focuses on the development of tesetaxel, an orally administered chemotherapy agent for patients with advanced or metastatic breast cancer (MBC). Odonate Therapeutics, Inc also conducting a Phase III study in MBC, which is known as CONTESSA.
Read More: Cash Flow
Receive News & Ratings for Odonate Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Odonate Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.